×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Phase 3 Study to Compare the Efficacy and Safety of Masitini
clinical
2,545 words
KG: Phase 3 Study to Compare the Efficacy and Safety of Masitini... (NCT03127267)
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
Contents
Phase 3 Study to Compare the Efficacy and Safety of Masitini... (NCT03127267)
Knowledge Graph
Related Hypotheses (14)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming
Score: 0.59
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Stress Granule Phase Separation Modulators
Score: 0.49
Cryptic Exon Silencing Restoration
Score: 0.46
Cross-Seeding Prevention Strategy
Score: 0.45
Glycine-Rich Domain Competitive Inhibition
Score: 0.43
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.37
Show 9 more
Related Analyses (7)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
Show 2 more
Related Experiments (3)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Proposed experiment from debate on Perivascular spaces and g
falsification · proposed · Score: 0.40
See Also (15)
Yoga Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
YAP/TEAD Pathway Modulators for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Wnt Signaling Modulators for Neurodegeneration
therapeutic · Pages share 4 hypotheses
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 4 hypotheses
Vitamin B Complex Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
VIP/VPAC Receptor Modulators for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Vestibular and Balance Therapy for CBS/PSP
therapeutic · Pages share 4 hypotheses
VEGF and Angiogenesis Therapy
therapeutic · Pages share 4 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 4 hypotheses
tudca-udca-neurodegeneration
therapeutic · Pages share 4 hypotheses
TRPM8 Agonists for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Triple Incretin Agonists (GLP-1/GIP/Glucagon) for Neuro
therapeutic · Pages share 4 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Transcranial Magnetic Stimulation Therapy for Neurodege
therapeutic · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (1 edges)
Phase 3 Study to Compare the Efficacy and Safety of Masitini... (NCT03127267)
references
TARDBP